RYBELSUS Drug Patent Profile

Which patents cover Rybelsus, and when can generic versions of Rybelsus launch?

Rybelsus is a drug marketed by Novo and is included in one NDA. There are fifteen patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in thirty-eight countries.

The generic ingredient in RYBELSUS is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Rybelsus

Rybelsus was eligible for patent challenges on December 5, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 15, 2033. This may change due to patent challenges or generic licensing.

There have been thirteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for RYBELSUS

International Patents:	192
US Patents:	15
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYBELSUS

Paragraph IV (Patent) Challenges for RYBELSUS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYBELSUS	Tablets	semaglutide	1.5 mg, 4 mg and 9 mg	213051	1	2025-12-11
RYBELSUS	Tablets	semaglutide	3 mg, 7 mg and 14 mg	213051	1	2024-07-15

US Patents and Regulatory Information for RYBELSUS

RYBELSUS is protected by fifteen US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-002	Sep 20, 2019		RX	Yes	Yes			Y
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-005	Dec 9, 2024		RX	Yes	Yes
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-006	Dec 9, 2024		RX	Yes	Yes			Y	Y
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-003	Sep 20, 2019		RX	Yes	Yes

International Patents for RYBELSUS

When does loss-of-exclusivity occur for RYBELSUS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RYBELSUS around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2827885
Serbia	57727	KOMPOZICIJE GLP-1 PEPTIDA I NJIHOVO DOBIJANJE (COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF)
South Korea	20200013078
Poland	2827885

Supplementary Protection Certificates for RYBELSUS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	2018/017	Ireland		PRODUCT NAME: OZEMPIC-SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	300936	Netherlands		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	SPC/GB18/023	United Kingdom		PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208
1863839	1890018-3	Sweden		PRODUCT NAME: SEMAGLUTIDE; REG. NO/DATE: EU/1/17/1251 20180212

Investment Scenario and Fundamentals Analysis for RYBELSUS

Last updated: February 19, 2026

What is RYBELSUS?

RYBELSUS (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. Approved by the FDA in September 2019 for type 2 diabetes (T2D), it is also marketed for weight management under the brand Wegovy (also semaglutide). RYBELSUS is an oral formulation, differentiating it from other injectable GLP-1 drugs.

Market Position and Growth Drivers

As of 2023, RYBELSUS holds approximately 25% of the oral diabetic treatment market. The drug competes mainly with injectable GLP-1s (Victoza, Trulicity) and SGLT2 inhibitors. Rapid adoption reflects favorable dosing convenience and robust efficacy.

Forecasts project a compound annual growth rate (CAGR) of 15% for semaglutide-based therapies until 2027, driven by expanding diabetes patient pool—estimated at 537 million globally in 2021—and increasing obesity prevalence.

Financial Performance

In 2022, RYBELSUS generated:

Metric	2022 Figures	Change (vs. 2021)
Sales (USD millions)	$3.2 billion	+50%
Market share (oral diabetes)	25%	+5 percentage points
Prescriptions (million)	6.2	+40%

Sales benefited from new European approvals and expanded indications. Gross margin is approximately 70%, with R&D expenses of about $1.2 billion in 2022, primarily for pipeline expansion.

Regulatory and Market Access

• Approved indications:
  • Type 2 diabetes (FDA, EMA)
  • Obesity management (FDA, approved 2021)
• Coverage:
  • Major markets provide insurance reimbursement, but formulary access varies.
• Pricing:
  • US list price: $974 per month (approximate)
  • Price discounts and negotiations influence net revenue.

Competitive Landscape

Competitor	Product	Mode of Action	Market Share (2023)	Key Differentiator
Eli Lilly	Trulicity	Injectable GLP-1	30%	Once-weekly injection
AstraZeneca	Bydureon	Injectable GLP-1	10%	Extended-release formulation
Novo Nordisk	Victoza	Injectable GLP-1	15%	Established brand
Eli Lilly	Mounjaro (tirzepatide)	Dual GIP/GLP-1 agonist	Emerging	Higher efficacy for weight

RYBELSUS’s oral route offers convenience, but injectable competitors maintain significant share due to established efficacy and branding.

Pipeline and Future Opportunities

• Obesity indication: Ongoing studies on dosage optimization and additional patient populations.
• Cardiovascular outcomes: Data suggests benefits similar to injectable GLP-1s, potentially expanding label approvals.
• Other indications: NASH, nonalcoholic fatty liver disease, under investigation.

Investment Risks

• Market penetration: Slow adoption among primary care physicians due to familiarity with injectables.
• Pricing pressure: Increasing competition could lead to price erosion.
• Regulatory delays: Any setbacks in pipeline approval or label extensions may impair growth.
• Generic competition: Patent expirations for key formulations forecasted around 2028, risking revenue erosion.

Valuation Considerations

Based on current sales trajectory, RYBELSUS could reach $6-8 billion in annual revenue globally by 2025. Applying an EV/Sales multiple of 10-12x for high-growth biotech assets yields an enterprise value estimate of $60-96 billion, factoring in pipeline potential.

Conclusion

RYBELSUS demonstrates strong revenue growth driven by increasing demand for easy-to-use diabetes and weight-loss therapies. The market is competitive, with notable growth potential from pipeline expansion and expanded indications. Risks include pricing pressures and regulatory hurdles, but the drug's current market dominance and Novo Nordisk’s R&D capacity support a favorable long-term outlook.

---

Key Takeaways

• RYBELSUS’s oral formulation positions it for rapid growth in diabetes and obesity markets.
• Sales are expanding at approximately 50% annually; global revenue could reach $6-8 billion by 2025.
• Competition from injectables remains significant; pipeline and label expansions could bolster market share.
• Patent expiry around 2028 suggests revenue stability for now but warrants monitoring.
• Valuation multiples imply enterprise value in excess of $60 billion, reflecting its growth prospects.

---

FAQs

1. What distinguishes RYBELSUS from injectable GLP-1 drugs?
It is the only oral GLP-1 receptor agonist approved for diabetes and weight management, offering convenience and compliance advantages.

2. How does RYBELSUS perform in terms of efficacy?
Clinical trials show comparable glycemic control and weight reduction to injectable GLP-1s, with significant improvements over placebo.

3. What are the main barriers to its widespread adoption?
Physician familiarity with injectables, formulary access issues, and patient acceptance of oral diabetics.

4. What is the competitive outlook for semaglutide-based therapies?
While RYBELSUS leads in oral formulations, injectable drugs maintain a large share; Eli Lilly’s Mounjaro is emerging with higher efficacy.

5. What is the risk of patent expiration?
Patents for RYBELSUS expire around 2028, risking generic competition, which could impact revenues unless extended or new formulations are developed.

---

Sources:
[1] Novo Nordisk Annual Report 2022.
[2] FDA Approval documentation for RYBELSUS.
[3] IQVIA, Global Drug Market Data, 2023.
[4] ClinicalTrials.gov, Semaglutide studies.
[5] MarketWatch, Diabetes drug market analysis, 2023.